Nikfar Shekoufeh, Rahimi Roja, Rahimi Fatemeh, Derakhshani Saeed, Abdollahi Mohammad
Drug Selecting Committee, Food and Drug Organization, Food & Drug Laboratory Research Center, Ministry of Health & Medical Education, Tehran, Iran.
Dis Colon Rectum. 2008 Dec;51(12):1775-80. doi: 10.1007/s10350-008-9335-z. Epub 2008 May 9.
This study was designed to evaluate whether probiotics improve symptoms in patients with irritable bowel syndrome.
PubMed, Embase, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched for studies that investigated the efficacy of probiotics in the management of irritable bowel syndrome. Clinical improvement was the key outcome of interest. Data were searched within the time period of 1966 through September 2007.
Eight randomized, placebo-controlled, clinical trials met our criteria and were included in the analysis. Pooling of eight trials for the outcome of clinical improvement yielded a significant relative risk of 1.22 (95 percent confidence interval, 1.07-1.4; P = 0.0042).
Probiotics may improve symptoms of irritable bowel syndrome and can be used as supplement to standard therapy.
本研究旨在评估益生菌是否能改善肠易激综合征患者的症状。
检索了PubMed、Embase、Scopus、Web of Science和Cochrane对照试验中心注册库，以查找研究益生菌治疗肠易激综合征疗效的研究。临床改善是主要关注的结果。在1966年至2007年9月期间检索数据。
八项随机、安慰剂对照临床试验符合我们的标准，并纳入分析。八项试验合并临床改善结果得出显著相对风险为1.22（95%置信区间，1.07 - 1.4；P = 0.0042）。
益生菌可能改善肠易激综合征的症状，并可作为标准治疗的补充。
Zotero 插件